Discretionary Assets Under Management (AUM) -- $23.1 billion, down 3.7% sequentially from $24 billion, primarily due to net ...

Among longtime history teacher Karalee Wong Nakatsuka’s most prized possessions are two nearly identical T-shirts with very ...

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is progressing well with the ...

Parex Resources Inc. (“Parex” or the “Company”) (TSX: PXT) is pleased to announce that the Company is poised to become Colombia’s largest independent oil and gas producer and to provide new corporate ...

HUYA Inc. ('Huya' or the 'Company') (NYSE: HUYA), a leading game-related entertainment and services provider, today announced its unaudited financial results for the first quarter ended March 31, 2026 ...

Kyntra Bio, Inc. (NASDAQ: KYNB) Q1 2026 Earnings Call Transcript May 11, 2026 Kyntra Bio, Inc. misses on earnings expectations. Reported EPS is $-3.76 EPS, expectations were $-3.36.

Oklahoma lawmakers are celebrating record education funding, but the state still ranks 49th in per-pupil spending nationally ...

The global Fiber and Specialty Carbohydrate Market is projected to grow from USD 15 billion in 2025 to USD 26.1 billion by 2035, expanding at a CAGR ...

If it feels like the roads and highways of Ontario aren’t as safe as they used to be, that’s because they aren’t. Two ...

First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected in 3Q 2026 Cash balance of ...

First-ever FDA approved PROTAC supports the further development and potential of Arvinas’ pipeline – – Announced FDA Approval ...

Revenue was $19.1 million in the first quarter of 2026, an increase of 3% compared to the same period in 2025 with unit growth of 13% compared to the same period in 2025. The increase was primarily ...